According to a media release issued this morning by Active Biotech and Ipsen, the companies have already enrolled 600 out of the 1,200 men with metastatic, castration-resistant prostate cancer (mCRPC) needed to complete the randomized, double-blind Phase III clinical trial of tasquinimod.
This trial started to enroll patients early in 2011, so it may take another year before the trial is fully enrolled — and another 18 months after that (i.e., until about mid to late 2014) until outcomes from this trial are available. More information about this trial is available on the ClinicalTrials.gov web site.
As we have noted earlier, the expanding number of effective agents available for the treatment of mCRPC is probably making it harder to enroll new patients into these clinical trials. Furthermore, by the time patients do enroll into these clinical trials, they may have more advanced forms of disease because they may have progressed on treatment with drugs like abiraterone acetate, MDV3100, and others.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resitant, mCRPC, metastatic, tasquinimod |
THE "NEW" PROSTATE CANCER INFOLINK 
Leave a Reply